Miratryp (Ulinastatin) is used in the treatment of severe sepsis and inflammation of the pancreas (acute pancreatitis). It helps to reduce the chemicals involved in inflammation of the pancreas.Ulinastatin is an acid-resistant protease inhibitor found in human urine and released from the high-molecular-weight precursor I alpha T1. Ulinastatin protein has been found in the brain, liver, kidney, gastrointestinal tract, cartilage, plasma, ovarian follicular fluid, amniotic fluid, and urine. Its mRNA has been detected only in the liver, kidney, heart, lungs, and pancreas.
Ulinastatin 100000 IU
MODE OF ACTION:
Trypsin secreted by the pancreatic acinar cells activates protease-activated receptor-2 which can result in the production of cytokines. Ulinastatin, which is a protease inhibitor, prevents trypsinogen to trypsin conversion and further activation of various enzymes and inflammatory response acute pancreatitis. In addition Ulinastatin inhibits the secretion of pro-inflammatory cytokines thus preventing further progression MODS in severe acute pancreatitis
Ulinastatin increases the serum level of fibrinogen and fibrinogen degradation products, thereby improving the coagulatory disturbance caused by sepsis
- Acute pancreatitis
- Severe sepsis
|Severe acute pancreatitis||2,00,000 I.U. BID for 5 days|
|Severe sepsis||2,00,000 I.U. BID for 5 days|
|Burns||1,00,000 I.U. TID for 5-10 days, may be repeated depending on severity|
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.